A New Target in TP53-Mutated Blood Cancers: Could Blocking PLEK2 Slow Disease Progression?

Changes to the TP53 gene are common in many blood cancers. This mutation can make people face more challenges with the therapies they receive. Researchers are working to understand the changes in cells when TP53 mutations are present. A new study highlights how this mutation affects a protein called PLEK2, and how this protein may be a promising target that may help slow disease progression in high-risk patients.

What is TP53 and why is it important in myeloid malignancies?

TP53 is a gene that helps control the cell cycle. It also repairs cell damage. The protein this gene produces is called p53. This protein has a crucial role in cell “quality control,”  and helps prevent abnormal cells from becoming cancerous.

In many myeloid malignancies, such as certain high-risk myeloproliferative neoplasms (MPNs) and leukemia, TP53 is mutated. When this happens, cancer cells can grow more aggressively and become resistant to treatment.

What is PLEK2, and how does it affect blood cancer cells?

PLEK2 (pleckstrin-2) is a protein involved in cell structure and signaling. Earlier research showed that it plays a role in MPNs, especially in cells with the JAK2 mutation, by helping cancer cells grow and survive.

When PLEK2 was blocked in lab models, it reduced blood clots and improved survival, without affecting normal blood cells.

In this study, researchers discovered that PLEK2 is directly controlled by p53. In healthy cells, p53 binds to the PLEK2 gene and keeps its activity low. When TP53 is mutated or missing, this control is lost. As a result, PLEK2 levels rise.

What happened when researchers blocked PLEK2 in TP53-deficient models?

To understand the impact, scientists created mouse models lacking both p53 and Plek2. Compared to mice missing only p53, those without both genes had:

• Partial normalization of blood counts
• Less severe disease features
• Significantly longer survival

They also studied how aggressive disease behaves in models that combined JAK2 mutation with p53 loss, similar to high-risk or leukemia-phase MPNs. In these models, PLEK2 levels increased as the disease progressed.

When researchers blocked PLEK2 with a medication, they observed:

• Reduced spleen size, which is important for lowering disease burden and improving blood counts. 
• Improved bone marrow appearance
• Less abnormal blood production
• Reduced blood clotting
• Extended survival

The importance of finding new targets in research for challenging diseases

TP53-mutated myeloid malignancies are often associated with poor prognosis and fewer effective treatment options. This research identifies PLEK2 as a key downstream driver of disease when TP53 is lost .

Targeting PLEK2 either genetically or with small-molecule inhibitors, improved blood counts, reduced complications like thrombosis (blood clots), and significantly extended survival in lab models. 

What should patients take away from this study?

It can be overwhelming to know that TP53 mutations are linked to more aggressive disease. But studies like this show that researchers are carefully mapping what happens inside cancer cells and identifying new targets for treatment.

By uncovering the p53–PLEK2 pathway, scientists have found a potential weakness in TP53-mutated blood cancers. Each discovery like this allows modern medicine to offer more personalized, effective therapies.

If you’re interested in finding a clinical trial suited to your specific needs visit HealthTree’s Clinical Trial Finder by clicking the button below. Explore clinical trials and apply filters to find personalized options. 

EXPLORE MORE CLINICAL TRIALS 

More research is needed to develop PLEK2-targeted treatments, including human clinical trials. 

Stay tuned for more news on innovative therapies, research and more with the HealthTree news site. 

READ MORE NEWS

Source:  Plek2 as a novel downstream effector of p53: Targeting Plek2 ameliorates disease

progression in p53-deficient myeloid malignancies